{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:02:09Z","timestamp":1787166129583,"version":"build-2736575974"},"reference-count":20,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.2967\/jnumed.122.264296","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T17:15:18Z","timestamp":1666890918000},"page":"227-231","source":"Crossref","is-referenced-by-count":22,"title":["Eligibility for\n                    <sup>177<\/sup>\n                    Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of\n                    <sup>68<\/sup>\n                    Ga-PSMA-11 and\n                    <sup>99m<\/sup>\n                    Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Gary J.R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Lup","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal","family":"Sanghera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Mangar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Challapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Leaning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidkonz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2023031310500867000_64.2.227.1","first-page":"349","article-title":"[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review","volume":"10","author":"Bois","year":"2020","journal-title":"Am J Nucl Med Mol Imaging."},{"key":"2023031310500867000_64.2.227.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2023031310500867000_64.2.227.3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263638"},{"key":"2023031310500867000_64.2.227.4","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol."},{"key":"2023031310500867000_64.2.227.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.187807"},{"key":"2023031310500867000_64.2.227.6","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.120.261289"},{"key":"2023031310500867000_64.2.227.7","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","article-title":"[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310500867000_64.2.227.8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023031310500867000_64.2.227.9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1148\/radiol.211824","article-title":"Effect of 18F-DCFPyL PET\/CT on the management of patients with recurrent prostate cancer: results of a prospective multicenter registry trial","volume":"303","author":"Metser","year":"2022","journal-title":"Radiology."},{"key":"2023031310500867000_64.2.227.10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.23444","article-title":"99mTc-MIP-1404-SPECT\/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer","volume":"78","author":"Schmidkonz","year":"2018","journal-title":"Prostate."},{"key":"2023031310500867000_64.2.227.11","first-page":"2679","article-title":"Tc-99m PSMA and Lu-177 PSMA theranostic pair in a patient of metastatic castration resistant prostate cancer","volume":"71","author":"Sheikh","year":"2021","journal-title":"JPMA J Pak Med Assoc."},{"key":"2023031310500867000_64.2.227.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.116624"},{"key":"2023031310500867000_64.2.227.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.140426"},{"key":"2023031310500867000_64.2.227.14","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40658-018-0239-2","article-title":"Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients","volume":"6","author":"Sandgren","year":"2019","journal-title":"EJNMMI Phys."},{"key":"2023031310500867000_64.2.227.15","first-page":"416","article-title":"Bayesian penalised likelihood (\u2018Q-clear\u2019) reconstruction of 68Ga-THP-PSMA PET\/CT in prostate cancer: a comparison with standard image reconstruction methods","volume":"40","author":"Chuah","year":"2019","journal-title":"Nucl Med Commun."},{"key":"2023031310500867000_64.2.227.16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40658-021-00400-8","article-title":"Standardisation of conventional and advanced iterative reconstruction methods for gallium-68 multi-centre PET-CT trials","volume":"8","author":"Krokos","year":"2021","journal-title":"EJNMMI Phys."},{"key":"2023031310500867000_64.2.227.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2023031310500867000_64.2.227.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2023031310500867000_64.2.227.19","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14876"},{"key":"2023031310500867000_64.2.227.20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bju.15384","article-title":"UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-na\u00efve prostate cancer (clinical trial protocol)","volume":"128","author":"Dhiantravan","year":"2021","journal-title":"BJU Int."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T13:53:35Z","timestamp":1678715615000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,1]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.2967\/jnumed.122.264296"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264296","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}